Cargando…

Gut microbiota: a potential therapeutic target for Parkinson’s disease

Detalles Bibliográficos
Autor principal:	Baizabal-Carvallo, José Fidel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896209/ https://www.ncbi.nlm.nih.gov/pubmed/32859778 http://dx.doi.org/10.4103/1673-5374.290896

Ejemplares similares

The role of viruses in the pathogenesis of Parkinson’s disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2020)

Anti-Gravity Treadmill Training for Freezing of Gait in Parkinson’s Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2020)

Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2021)

Objective and self-perceived lower limb weakness in Parkinson’s disease
por: Alonso-Juarez, Marlene, et al.
Publicado: (2022)

The Role of Muscle Strength in the Sit-to-Stand Task in Parkinson's Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2023)

Recognizing Uncommon Presentations of Psychogenic (Functional) Movement Disorders
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2015)

The Clinical Characterization of Blocking Tics in Patients With Tourette Syndrome
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2023)

Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
por: Zhu, Manlian, et al.
Publicado: (2022)

Genetics provides new individualized therapeutic targets for Parkinson’s disease
por: Garcia, Eric Joshua, et al.
Publicado: (2020)

Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
por: Gabrielli, Giulia, et al.
Publicado: (2023)

Role of the Gut Microbiota in Children with Kidney Disease
por: Tain, You-Lin, et al.
Publicado: (2023)

Sigma-1 receptor: a potential new target for Parkinson's disease?
por: Francardo, Veronica
Publicado: (2014)

Functional (Psychogenic) Movement Disorders Presenting During Sleep
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2021)

Contrasting features between Tourette syndrome and secondary tic disorders
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2023)

Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
por: Yoshikawa, Sayuri, et al.
Publicado: (2023)

Emerging non-invasive therapeutic approaches targeting hypocholinergic neural systems in Parkinson’s disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2022)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Limited therapeutic potential of astrocyte elevated gene-1 transduction in an animal model of Parkinson's disease
por: Leem, Eunju, et al.
Publicado: (2020)

SLP-2: a potential new target for improving mitochondrial function in Parkinson's disease
por: Zanon, Alessandra, et al.
Publicado: (2017)

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications
por: Zhang, Fen, et al.
Publicado: (2022)

The Influence of Dietary Factors on the Gut Microbiota
por: Nova, Esther, et al.
Publicado: (2022)

Inhibition of microglial activation and induction of neurotrophic factors by flavonoids: a potential therapeutic strategy against Parkinson's disease
por: Kim, Sang Ryong
Publicado: (2015)

Gut microbiota–derived short-chain fatty acids and kidney diseases
por: Li, Lingzhi, et al.
Publicado: (2017)

Interaction between Gut Microbiota and Celiac Disease: From Pathogenesis to Treatment
por: Rossi, Roberta Elisa, et al.
Publicado: (2023)

Is EAAT2 a potential therapeutic intervention target for Alzheimer’s disease?
por: Wood, Oliver WG, et al.
Publicado: (2023)

Potential role of biofeedback therapy for Parkinson’s disease
por: Kotani, Naoya, et al.
Publicado: (2021)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

Targeting transglutaminase 2 as a potential disease modifying therapeutic strategy for synucleinopathies
por: Zhang, Jie, et al.
Publicado: (2021)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COVID-19 Severity?
por: Kim, Heenam Stanley
Publicado: (2021)

Gut microbiota in inflammatory bowel diseases: moving from basic science to clinical applications
por: Collij, Valerie, et al.
Publicado: (2020)

Ancient Thali Diet: Gut Microbiota, Immunity, and Health
por: Shondelmyer, Kaitlyn, et al.
Publicado: (2018)

New research frontiers pertaining to the infant gut microbiota
por: Ventura, Marco, et al.
Publicado: (2022)

Targeting chaperone-mediated autophagy for Parkinson’s disease therapy
por: Wang, Yi-Ting, et al.
Publicado: (2023)

Leaky gut, dysbiosis, and enteric glia activation: the trilogy behind the intestinal origin of Parkinson’s disease
por: Seguella, Luisa, et al.
Publicado: (2019)

Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
por: Belli, Martina, et al.
Publicado: (2023)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

Nutrient-Sensing Mechanisms in the Gut as Therapeutic Targets for Diabetes
por: Breen, Danna M., et al.
Publicado: (2013)

New hope for Parkinson's disease treatment: Targeting gut microbiota
por: Fan, Hong‐Xia, et al.
Publicado: (2022)

Cross-talk between T-cells and gut-microbiota in neurodegenerative disorders
por: Pacheco, Rodrigo
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hbk318q4ebpq4bshf5mga2hsa5